Skip to main content
Clinical Trials/NCT01508754
NCT01508754
Completed
Phase 4

Efficacy of Continuous Positive Airway Pressure (CPAP) on Blood Pressure Control of Resistant Hypertension Patients With Obstructive Sleep Apnea Syndrome (OSAS).

Universidade Federal do Rio de Janeiro1 site in 1 country125 target enrollmentJanuary 2012

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Obstructive Sleep Apnea Syndrome
Sponsor
Universidade Federal do Rio de Janeiro
Enrollment
125
Locations
1
Primary Endpoint
clinic and ambulatory blood pressures
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The aim is to evaluate the effect of treatment with Continuous Positive Airway Pressure (CPAP) device on clinic and ambulatory blood pressures (BP) of 200 resistant hypertensive patients with moderate-severe obstructive sleep apnea syndrome (OSAS).

Detailed Description

Obstructive sleep apnea syndromes (OSAS) have been demonstrated to be highly prevalent in patients with resistant hypertension (defined as uncontrolled clinic BP despite being on anti-hypertensive treatment with at least 3 drugs in optimal doses and including a diuretic). Nevertheless, the effect of treating OSAS with Continuous Positive Airway Pressure (CPAP) device on clinic and ambulatory BPs in patients with resistant hypertension is largely unknown. Hence, the primary aim of this randomized clinical trial is to evaluate the effect of CPAP on BP levels in resistant hypertensive patients with moderate-severe OSAS (defined as an apnea-hypopnea index \[AHI\] greater than 15 on a full polysomnographic examination). Two-hundred patients will be randomly allocated either to treatment with CPAP device plus their usual anti-hypertensive treatment or to continue their usual treatment alone for 6 months. Clinic and 24-hour ambulatory BP monitoring, laboratory evaluation (including microalbuminuria and aldosterone-to-renin ratio), 24-hour Holter monitoring, ergospirometric treadmill test, and carotid-femoral pulse wave velocity measurement will be performed before and after the 6-month treatment, with the observers blinded to the allocation group.

Registry
clinicaltrials.gov
Start Date
January 2012
End Date
August 2014
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Gil Fernando da Costa Mendes de Salles, PhD

Full Professor, Faculty of Medicine

Universidade Federal do Rio de Janeiro

Eligibility Criteria

Inclusion Criteria

  • Patients with resistant hypertension and moderate-severe obstructive sleep apnea syndrome

Exclusion Criteria

  • Older than 80 years
  • Pregnant women
  • Non-adherent to anti-hypertensive treatment
  • Severe cognitive deficits

Outcomes

Primary Outcomes

clinic and ambulatory blood pressures

Time Frame: 6 months

Clinic and ambulatory blood pressures (during 24-hour ambulatory blood pressure monitoring, which included both daytime and nighttime blood pressures, as well as the nocturnal dipping pattern).

Secondary Outcomes

  • Arterial stiffness(6 months)
  • Aldosterone excess measurements(6 months)
  • Autonomic system measurements(6 months)
  • Cardiorespiratory fitness(6 months)
  • Microalbuminuria(6 months)

Study Sites (1)

Loading locations...

Similar Trials